+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Clinical Trials in Osteosarcoma

Osteosarcoma Institute

The primary objective of proposed Phase I/II or Phase II clinical trials in relapsed/refractory osteosarcoma should be to improve event free survival (EFS) at 4 months beyond historical rates known to be in the range of 12% for patients with unresectable disease. The proposed trial may be carried out in a single institution, a clinical trial consortium, or through an existing clinical trial infrastructure. The OSI will not prioritize the launch of new infrastructures to conduct clinical trials. Please provide specific timetables for protocol development, regulatory approvals, industry agreements, IRB approvals, activation, accrual, and reporting. We will consider the applicant’s history of efficiently entering agreements, opening trials, and meeting accrual expectations for trials of relapsed osteosarcoma patients, with the expectation that results will be available within three years of trial initiation. Other desirable characteristics for proposals include:

• Answering an important question

• Strong preclinical rationale

• Rigorous trial design and correlative endpoints to allow for productive failure

• Budget reasonableness (per patient and total)

• Leverage from concurrent financial support of the trial (e.g., direct institutional support, industry and/or philanthropic support, securing drug, etc.)

BUDGET Up to $800,000 total over two to three years (inclusive of indirect costs not to exceed 10% of the requested project budget).

AI Based Application Success Predictor

1. Laser Focus on Osteosarcoma Patient Impact

OSI exclusively funds projects that meaningfully accelerate treatments, particularly for:

Relapsed or refractory osteosarcoma

Metastatic disease (especially lung metastasis)

Therapeutic resistance and relapse biology

Clinically actionable targets

Priority topics include:

Immunotherapy (T/NK cell, vaccines, IO combinations)

Target discovery & validation

Drug repurposing or novel small molecules

Precision medicine strategies (genomic, proteomic)

Biomarkers predicting response or relapse

Minimal residual disease (MRD) and monitoring tools

Metastasis inhibition

❗ Basic bone/sarcoma biology without a clear therapeutic implication rarely gets funded.

2. Fit With the OSI Mechanism

OSI offers mechanisms aligned to translational stage:

Mechanism	Best For	Key Criteria
Clinical Trial Grants	Investigator-initiated OS trials	Patient access, delivery timeline, safety & endpoints
Translational Grants	Bridging lab → clinic	Strong preliminary data + clear therapeutic pathway
Drug Development / Accelerator Funding	Industry or academia–industry	IND-enabling or near-clinical compounds

Predictor: Match your development stage to the mechanism: discovery → validation → translation → trial.

3. Robust Preliminary Data

OSI expects feasibility evidence:

Target expression/essentiality

Early efficacy in OS models

Pharmacokinetic/toxicity data (if drug-focused)

Proof of access to relapsed OS cohorts or samples

Pilot biomarker signals

Predictor: Strong preliminary data is a top determinant of success.

4. Osteosarcoma-Relevant Models

Models must clearly reflect human OS disease:

Patient-derived xenografts (PDX)

OS lung metastasis models

Canine OS as a translational bridge

CRISPR or humanized OS models

OS organoids or 3D cultures

Omics-driven subtype stratification

Predictor: OS-specific and metastasis-relevant models are critical for translational value.

5. Clear, Near-Term Clinical Trajectory

Winning proposals articulate a stepwise path toward patient benefit, including:

Defined translational milestones

Criteria for progressing to clinical trial

Endpoints that enable FDA engagement

Roadmap for CMC, toxicity, patient accrual (if applicable)

Predictor: “Therapy acceleration” must be undeniable.

6. Access to Osteosarcoma Patient Cohorts

Especially for clinical/translational awards:

Access to relapse and metastatic patients

Clinical sample biobanks

Imaging/pathology data

Partnerships with COG/SARC groups or major sarcoma centers

Predictor: Demonstrated access to relevant patients boosts feasibility.

7. Experienced Team & Necessary Partnerships

Top-scoring proposals include:

Clinician–scientist involvement

Experts in drug development, immunology, or metastasis biology

Cross-institutional collaborations

Industry partnership for IND/CMC/trial readiness

Predictor: Proven expertise + collaboration improves reviewer confidence.

8. Focused Aims with Measurable Milestones

OSI funding is milestone-driven.

Best proposals have:

2–3 focused, hypothesis-driven aims

Concrete deliverables (e.g., “IND submission-ready PK/PD dataset”)

Risk mitigation strategies

Clear timelines & go/no-go checkpoints

Predictor: Clarity + feasibility = higher scores.

9. Alignment With Unmet Needs

Highest priority for:

Relapsed/refractory disease

Rare OS subtypes

Therapies for patients with limited options

Early detection of metastasis or relapse

Reducing treatment toxicity in young patients

Predictor: Targeting urgent care gaps strengthens impact.

10. Clear Communication & Persuasiveness

Reviewers appreciate proposals that are:

Direct and well-written

Supported by compelling figures

Easy to follow for clinicians, scientists, and drug developers

Strong in statistical and regulatory rationale (if clinical)

Predictor: Professional-quality writing improves enthusiasm.

🏆 Summary Table — OSI Proposal Success Predictors

Predictor	Why It Matters
Osteosarcoma-specific focus	Core mission
Mechanism alignment	Expected progress level
Strong preliminary data	Demonstrates feasibility
Relevant OS models	Ensures translational relevance
Near-term clinical trajectory	OSI’s core goal
Patient access	Critical for clinical translation
Collaboration	Execution & expertise assurance
Focused aims	Fits OSI’s milestone-driven model
Address unmet needs	Aligns with mission urgency
Clear writing & rationale	Improves reviewer scoring

Specialties

Cancer

Eligibility Requirements

• Funds must be granted to nonprofit/charitable institutions or organizations. While we allow for any individual institution to submit multiple LOI submissions, we are unlikely to fund more than one grant per institution in any grant cycle.

• Grantee organization does not need to be based in the United States. o However, in order to fund a foreign entity, the OSI requires documentation that if the entity were a United States-based organization, the entity would qualify as a charitable organization. This is usually relatively straightforward when dealing with entities in countries with a tax regime similar to the U.S. by way of a government-issued letter or other document designating the entity as a charitable institution or as performing a charitable purpose (for example, research or education). It might also be a determination from the relevant taxing authority that the entity qualifies for tax-deductible contributions.

• Applicants need not be United States citizens.

• Applicants must have an MD, PhD, MD/PhD, or equivalent and be appointed as faculty (or equivalent) at an academic institution.

• Applicants must have a track record of publication and funding productivity that demonstrates the project can be accomplished by the investigators.

• Research projects may be an extension of ongoing research but cannot overlap with any funded studies unless the applicant clearly demonstrates that new funding will not duplicate existing support.

• Applicants can submit only one (1) Letter of Intent (LOI).

• Applicants selected for funding will permit the OSI to publicize the grant for fundraising purposes, including, but not limited to a five-minute video discussing the research project, photos of lab, and photos of children participating in clinical trials, where applicable.

• Applications that do not follow the specific grant application instructions and/or submission process will not be considered.

• Applications received after the due date will not be considered. • Applications which do not fall under the OSI mission will not be considered.

• Resubmissions: Only one resubmission of a previously reviewed application is permitted.

Sponsor Details

Sponsor Institute/Organizations: Osteosarcoma Institute

Sponsor Type: Corporate/Non-Profit

Address: 3963 Maple Avenue Suite 390 Dallas, TX 75219

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity